Original Research

DOI: 10.4244/EIJ-D-25-00005

Impact of complete revascularisation in relation to left ventricular function in patients with ST-segment elevation myocardial infarction and multivessel disease: a post hoc analysis of the COMPLETE randomised trial

Denise Tiong1, MD; Natalia Pinilla-Echeverri1,2, MD, PhD; David A. Wood3, MD; Roxana Mehran4, MD; Robert F. Storey5, MD; Laurent Feldman6, MD, PhD; Raul Moreno7, MD, PhD; Sunil Rao8, MD; Warren J. Cantor9, MD; Robert Welsh10, MD; Kevin R. Bainey10, MD, MSc; Eric A. Cohen11, MD; Michael B. Tsang1, MD; Matthew Sibbald1, MD, PhD; Madhu K. Natarajan1, MD, MSc; Dilani Wijesena2, MSc; Thenmozhi Mani2, PhD; Helen Nguyen2, BSc; John A. Cairns3, MD; Shamir R. Mehta1,2, MD, MSc

Abstract

Background: The COMPLETE trial demonstrated a reduction in cardiovascular (CV) death or new myocardial infarction (MI) after complete, rather than culprit-only, revascularisation in patients with ST-segment elevation myocardial infarction (STEMI) and multivessel disease (MVD). However, it is unknown whether this benefit varies according to baseline left ventricular ejection fraction (LVEF).

Aims: We aimed to determine the effects of complete versus culprit-only revascularisation according to LVEF.

Methods: Baseline LVEF was available for 2,214 of 4,041 randomised patients. The effect of both strategies on the first co-primary outcome of CV death or new MI and the second co-primary outcome of CV death, new MI, or ischaemia-driven revascularisation (IDR) was determined within the prespecified LVEF ranges of <45% (N=660) and ≥45% (N=1,554). An analysis of clinical outcomes by LVEF according to thirds was also conducted.

Results: Patients with LVEF <45% experienced a significantly higher incidence of the first co-primary outcome compared with those with LVEF ≥45% (4.2%/year vs 2.8%/year; hazard ratio [HR] 1.51, 95% confidence interval [CI]: 1.15-1.98; p=0.003). Compared with a culprit-only strategy, complete revascularisation consistently reduced the first co-primary outcome in patients with LVEF <45% (3.0%/year vs 5.5%/year; HR 0.55, 95% CI: 0.36-0.86) and those with LVEF ≥45% (2.4%/year vs 3.2%/year; HR 0.74, 95% CI: 0.52-1.04; interaction p=0.31). Complete revascularisation also consistently reduced the second co-primary outcome in patients with LVEF <45% (3.5%/year vs 7.3%/year; HR 0.49, 95% CI: 0.33-0.74) and those with LVEF ≥45% (2.7%/year vs 6.3%/year; HR 0.44, 95% CI: 0.33-0.60; interaction p=0.67). Consistent results were observed for both co-primary outcomes when LVEF was further stratified into categories of LVEF ≤35%, 36-49% and ≥50%.

Conclusions: Among patients presenting with STEMI and MVD, those with reduced LVEF are at higher risk of ischaemic events than patients with preserved LVEF. There is a consistent benefit of complete revascularisation regardless of baseline LVEF.

Sign in to read
the full article

Forgot your password?
No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Volume 21 Number 20
Oct 20, 2025
Volume 21 Number 20
View full issue


Key metrics

Suggested by Cory

State-of-the-Art Review

10.4244/EIJ-D-20-00957 Jun 25, 2021
Completeness of revascularisation in acute coronary syndrome patients with multivessel disease
Paradies V et al
free

10.4244/EIJV16I3A34 Jun 25, 2020
Complete revascularisation in the STEMI patient: is it worth the effort?
Gershlick A and Banning AS
free

Original Research

10.4244/EIJ-D-23-00882 Jul 15, 2024
Immediate versus staged complete revascularisation in patients presenting with STEMI and multivessel disease
Scarparo P et al
free

Debate

10.4244/EIJ-E-23-00045 Feb 5, 2024
Complete revascularisation should be immediate in STEMI: pros and cons
Kastrati A et al
free

Letter to the editor

10.4244/EIJ-D-25-00325 Jun 16, 2025
Reply: Completeness or complexity? A nuanced reflection on multivessel revascularisation
Laudani C et al
free
Trending articles
318.3

State-of-the-Art Review

10.4244/EIJ-D-21-00695 Nov 19, 2021
Transcatheter treatment for tricuspid valve disease
Praz F et al
free
116.5

State-of-the-Art

10.4244/EIJ-D-24-00066 Apr 21, 2025
Management of complications after valvular interventions
Bansal A et al
free
108.3

Viewpoint

10.4244/EIJ-E-22-00007 May 15, 2022
TAVI at 20: how a crazy idea led to a clinical revolution
Eltchaninoff H et al
free
91.6

Image – Interventional flashlight

10.4244/EIJ-D-22-00344 Aug 5, 2022
First dedicated transcatheter leaflet splitting device: the ShortCut device
Tchétché D et al
free
72.15

State-of-the-art

10.4244/EIJ-D-22-00627 Feb 6, 2023
Left atrial appendage occlusion
Holmes D et al
free
68.9

State-of-the-Art

10.4244/EIJ-D-24-00992 Sep 15, 2025
Antithrombotic therapy in complex percutaneous coronary intervention
Castiello D et al
free
49.55

CLINICAL RESEARCH

10.4244/EIJ-D-17-00962 Apr 6, 2018
A new optical coherence tomography-based calcium scoring system to predict stent underexpansion
Fujino A et al
free
42.95

State-of-the-Art Review

10.4244/EIJ-D-21-00145 Sep 20, 2021
Robotics, imaging, and artificial intelligence in the catheterisation laboratory
Beyar R et al
free
X

PCR
Impact factor: 9.5
2024 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2025)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2025 Europa Group - All rights reserved